DOCSLIB.ORG

Vedlegg INSPIRE:Lungekreft 1 Virkestoff, Type Behandling, Tilordning

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vedlegg INSPIRE:Lungekreft 1 Virkestoff, Type Behandling, Tilordning Vedlegg INSPIRE:lungekreft 1 Virkestoff, type behandling, tilordning A B CD E G 1 Virkestoff_tilordning_mapping Virkestoff_fra sykehusene ATC-kode ATC nivå 2 ATC nivå 3 Type behandling_gruppert 2 Afatinib afatinib L01XE13 Antineoplastiske midler Andre antineoplastiske midler Proteinkinasehemmere 3 Aflibercept/Placebo Aflibercept/Placebo Ingen Utprøving 4 Alektinib alektinib L01XE36 Antineoplastiske midler Andre antineoplastiske midler Proteinkinasehemmere 5 Alemtuzumab ALEMTUZUMAB L04AA34 Immunsuppressiver Immunsuppressiver Immunterapi 6 Alemtuzumab Alemtuzumab L04AA34 Immunsuppressiver Immunsuppressiver Immunterapi 7 Alemtuzumab Alemtuzumab act-1 L04AA34 Immunsuppressiver Immunsuppressiver Immunterapi 8 Alemtuzumab Alemtuzumab HOVON 68 L04AA34 Immunsuppressiver Immunsuppressiver Immunterapi 9 Alemtuzumab zzz Alemtuzumab ACT-1-studien L04AA34 Immunsuppressiver Immunsuppressiver Immunterapi 10 Amphinex PCI A202 12 Amphinex PCI A202 12 Ingen Utprøving 11 Amphinex PCIA 203 18 Amphinex PCIA 203 18 Ingen Utprøving 12 Amsakrin AMSAKRIN L01XX01 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 13 Amsakrin Amsakrin L01XX01 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 14 Amsakrin Amsakrin HOVON 102 AML/SAKK L01XX01 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 15 Antitymocytt immunglobulin Anti-human thym. imm. (Kanin) L04AA04 Immunsuppressiver Immunsuppressiver Immunterapi 16 Antitymocytt immunglobulin Anti-humant T-lymfocyt imm.globulin (ATG) (Kanin) L04AA04 Immunsuppressiver Immunsuppressiver Immunterapi 17 Antitymocytt immunglobulin Anti-thym. globulin (Eq.= Hest) L04AA04 Immunsuppressiver Immunsuppressiver Immunterapi 18 Antitymocytt immunglobulin ATG Kanin (Genzyme) L04AA04 Immunsuppressiver Immunsuppressiver Immunterapi 19 Aprepitant Aprepitant A04AD12 Støttebehandling 20 Arfolitixorin Arfolitixorin ISO-CC-005 Ingen Utprøving 21 Arsentrioksid Arsenikk trioksid L01XX27 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 22 Arsentrioksid Arsenikktrioksid L01XX27 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 23 Arsentrioksid Arseniktrioksid L01XX27 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 24 Arsentrioksid Arsentrioksid L01XX27 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 25 Arsentrioksid ARSENTRIOKSID L01XX27 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 26 Arsentrioksid Arsentrioxid L01XX27 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 27 Asparaginase ASPARAGINASE L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 28 Asparaginase Asparaginase L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 29 Asparaginase ASPARAGINASE (Erwinase) L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 30 Asparaginase Asparaginase (Erwinase) i.m. injeksjon L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 31 Asparaginase Asparaginase bolus L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 32 Asparaginase Asparaginase Erwinase L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 33 Asparaginase Asparaginase medac L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 34 Asparaginase Erwinia L-asparaginase L01XX02 Antineoplastiske midler Andre antineoplastiske midler Kjemoterapi 35 Atezolizumab ATEZOLIZUMAB L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 36 Atezolizumab Atezolizumab L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 37 Atezolizumab Atezolizumab ACHILES L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 38 Atezolizumab Atezolizumab ACHILES/MO40379 L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 39 Atezolizumab Atezolizumab ACHILES-studie L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 40 Atezolizumab Atezolizumab BEATcc L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 41 Atezolizumab Atezolizumab Com-IT PD-L1 neg L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 42 Atezolizumab Atezolizumab Com-IT PD-L1 pos L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 43 Atezolizumab Atezolizumab Com-IT-1 L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi Vedlegg INSPIRE:lungekreft 2 Virkestoff, type behandling, tilordning A B CD E G 44 Atezolizumab Atezolizumab ML40718 ComIT1 L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 45 Atezolizumab Atezolizumab MO40379 ACHILES L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 46 Atezolizumab Atezolizumab VB C-02 L01XC32 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 47 Atezolizumab/placebo Atezolizumab/Placebo ALICE Ingen Utprøving 48 Atezolizumab/placebo Atezolizumab/placebo ALICE Ingen Utprøving 49 Atezolizumab/placebo Atezolizumab/placebo ALICE ML39079 Ingen Utprøving 50 Atezolizumab/placebo Atezolizumab/placebo IMagyn050 Ingen Utprøving 51 Atezolizumab/placebo Atezolizumab/placebo YO39523 IMAGYN Ingen Utprøving 52 Atropin Atropin A03BA01 Støttebehandling 53 AUY922 AUY922 (Studiemedisin) Ingen Utprøving 54 AUY922 AUY922 studie Ingen Utprøving 55 AUY922 zzz AUY922 studie A2206 Ingen Utprøving 56 Avelumab Avelumab L01XC31 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 57 Avelumab Avelumab B9991001 L01XC31 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 58 Avelumab Avelumab B9991009 L01XC31 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 59 Avelumab Avelumab Named Patient Use L01XC31 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 60 Avelumab Avelumab Studie B9991001 L01XC31 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 61 Azacitidin AZACITIDIN L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 62 Azacitidin Azacitidin L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 63 Azacitidin Azacitidin AML16 L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 64 Azacitidin Azacitidin s.c. injeksjon L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 65 Azacitidin Azacitidin subcutan L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 66 Azacitidin Azacitidine L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 67 Azacitidin Azacitidine s.c. L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 68 Azacitidin Azacitidine s.c. SUPPORT TRC112121 L01BC07 Antineoplastiske midler Antimetabolitter Kjemoterapi 69 Bendamustin BENDAMUSTIN L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 70 Bendamustin Bendamustin L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 71 Bendamustin Bendamustine L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 72 Bendamustin Bendamustine ENRICH L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 73 Bendamustin Bendamustine hcl L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 74 Bendamustin Bendamustine PREBEN L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 75 Bendamustin Bendamustine PREBEN-studien L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 76 Bendamustin Bendamustinhydroklorid L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 77 Bendamustine zzz Bendamustine LENA-BERIT NLG-MCL4-studien L01AA09 Antineoplastiske midler Alkyleringsmidler Kjemoterapi 78 Bevacizumab BEVACIZUMAB L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 79 Bevacizumab Bevacizumab L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 80 Bevacizumab Bevacizumab 177 L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 81 Bevacizumab Bevacizumab BEATcc L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 82 Bevacizumab Bevacizumab BOOST-studien OVAR17 L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 83 Bevacizumab Bevacizumab IMagyn050 L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 84 Bevacizumab Bevacizumab MAVERICC L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 85 Bevacizumab Bevacizumab NeoAva L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 86 Bevacizumab Bevacizumab NEOAVA studie L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi Vedlegg INSPIRE:lungekreft 3 Virkestoff, type behandling, tilordning A B CD E G 87 Bevacizumab Bevacizumab OCTAVIA-STUDIE L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 88 Bevacizumab Bevacizumab OVAR17 L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 89 Bevacizumab Bevacizumab TML-Studien L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 90 Bevacizumab Bevacizumab utenom studie L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 91 Bevacizumab Bevacizumab YO39523 IMAGYN L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 92 Bevacizumab Bevazicumab - Studie L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 93 Bevacizumab Bevazicumab-ICON7-studie L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 94 Bevacizumab zzz Bevacizumab Aurelia MO22224-studien L01XC07 Antineoplastiske midler Andre antineoplastiske midler Immunterapi 95 Bevacizumab zzz Bevacizumab ICON7-studien
Load more

Recommended publications
  • Understanding Understanding Non-Hodgkin Non-Hodgkin Lymphoma Lymphoma This Patient Guide Is Supported Through Unrestricted Educational Grants From
    Understanding Understanding Non-Hodgkin Non-Hodgkin Lymphoma Lymphoma This patient guide is supported through unrestricted educational grants from: A Guide for Patients, 8th Edition Survivors, and Loved Ones Contact the Lymphoma Research Foundation Helpline: (800) 500-9976 [email protected] Website: lymphoma.org Fall 2020 Lymphoma Research Foundation (LRF) Helpline and Clinical Trials FOCUS ON LYMPHOMA Information Service MOBILE APP CONTACT THE LRF HELPLINE The Lymphoma Research Foundation’s Trained staff are available to answer questions mobile app, Focus on Lymphoma, is a and provide support to patients, caregivers and great tool and resource for lymphoma healthcare professionals in any language. patients to manage their disease. Our support services include: Focus on Lymphoma is the fi rst mobile • Information on lymphoma, treatment options, app that provides patients and side effect management and current research fi ndings caregivers comprehensive content • Financial assistance for eligible patients and based on their lymphoma subtype and tools to help manage their diagnosis, referrals for additional fi nancial, legal and including a medication manager, doctor sessions tool and side effects tracker. insurance help • Clinical trial searches based on patient’s The Focus on Lymphoma mobile app was recently named Best App by PR News and diagnosis and treatment history is available for free download for iOS and Android devices in the Apple App Store • Support through LRF’s Lymphoma Support and Google Play. Network, a national one-to one volunteer patient peer program For further information on LRF’s award winning mobile app or any of our Monday through Friday programs and services, call the LRF Helpline toll free (800) 500-9976, 9:30 am − 7:30 pm Eastern Standard Time (EST) Toll-Free (800) 500-9976 email [email protected] or visit us at lymphoma.org.
    [Show full text]
  • Journal of Cancer Biology and Therapeutics
    ISSN: 2379-5972 Research Article Journal of Cancer Biology and Therapeutics Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma Xenografts Heyerdahl H*, Repetto-Llamazares AHV and Dahle J Department of Research and Development, Nordic Nanovector ASA, Norway *Correspondence: Helen Heyerdahl, Department of Research and Development, Nordic Nanovector ASA, Kjelsåsveien 168 B, 0884 Oslo, Norway, Tel: +(47) 22 18 33 01; Fax: +(47) 22 58 00 07; E-mail: [email protected] Received: Apr 20, 2018; Accepted: Aug 23, 2018; Published: Aug 28, 2018 Abstract Lutetium (177Lu) lilotomab satetraxetan (177Lu-lilotomab) is a novel anti-CD37 radioimmunoconjugate (RIC) currently in Phase 2b clinical trial for treatment of non-Hodgkin lymphoma (NHL). The aim of the current study was to investigate tolerability and anti-tumor efficacy of multiple dosing of 177Lu-lilotomab in vivo. Nude mice with subcutaneous (s.c.) NHL (Ramos) xenografts were given 2, 3 or 4 weekly injections of 300 MBq/kg 177Lu-lilotomab or NaCl. Treatment tolerability was assessed by body weight, hematology and histopathological evaluation. A separate experiment in mice without xenografts was performed to collect long term toxicity data. Mice in this study were dosed more conservatively with the intention that all mice should survive until end of experiment and were administered 2 or 4 weekly injections of 200 MBq/kg 177Lu-lilotomab or NaCl. Total accumulated activity of 900 MBq/kg 177Lu-lilotomab given as three weekly injections was tolerated by nude mice with s.c. Ramos xenografts, which is 50 % higher than the maximum tolerated activity (MTA) of a single injection of 530-600 MBq/kg.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Combination of 177Lu‐Lilotomab with Rituximab Significantly Improves The
    Received: 18 April 2018 | Accepted: 5 July 2018 DOI: 10.1111/ejh.13139 ORIGINAL ARTICLE Combination of 177Lu- lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non- Hodgkin’s lymphoma Ada H. V. Repetto-Llamazares1 | Marion M. Malenge1,2,3 | Adam O’Shea1 | Bergthóra Eiríksdóttir4 | Trond Stokke2 | Roy H. Larsen5 | Jostein Dahle1 1Nordic Nanovector ASA, Oslo, Norway Abstract 2Department of Radiation Biology, Institute for Cancer Research, Oslo University Objectives: To investigate the therapeutic potential of the next- generation anti- CD37 ra- Hospital, Oslo, Norway dioimmunoconjugate 177Lu- lilotomab satetraxetan (177Lu- lilotomab) in combination with 3Institute of Clinical Medicine, Faculty of the anti- CD20 antibody rituximab for treatment of mice with non- Hodgkin’s lymphoma Medicine, University of Oslo, Oslo, Norway 4ArcticLAS Ltd. CRO, Reykjavík, Iceland (NHL) xenografts. 5Sciencons AS, Oslo, Norway Methods: Nude mice with subcutaneous (s.c.) Burkitt’s lymphoma Daudi xenografts and SCID mice intravenously (i.v.) injected with Mantle cell lymphoma Rec- 1 cells were Correspondence 177 Ada H. V. Repetto-Llamazares, Nordic treated with either Lu- lilotomab or rituximab alone or with the combination of both Nanovector ASA, Kjelsåsveien 168B, 0884 treatments. Tumour volume, body weight, blood counts and clinical status were moni- Oslo, Norway. Email: [email protected] tored. CD20 expression was measured using flow cytometry with fluorescence- labelled rituximab. Funding information 177 Norges Forskningsråd, Grant/Award Results: The combination of Lu- lilotomab and rituximab was synergistic for treat- Number: Industrial PhD program, project ment of nude mice with s.c. Daudi xenografts while it was additive for treatment of number 260203; Nordic Nanovector ASA SCID mice with i.v.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
    INN Working Document 18.435 31/05/2018 Addendum1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2013.1 Programme on International Nonproprietary Names (INN) Technologies Standards and Norms (TSN) Regulation of Medicines and other health technologies (RHT) World Health Organization, Geneva © World Health Organization 2018 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme. This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization. Addendum1 to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1 1 This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2013. ------------------------------------------------------------------------------------------------------------ -apt- aptamers, classical and mirror ones (a) avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptepid pegol (108), olaptesed pegol (109), pegaptanib (88) (b) -vaptan stem: balovaptan (116), conivaptan
    [Show full text]
  • Understanding Non-Hodgkin Lymphoma
    Understanding Non-Hodgkin Lymphoma A Guide for Patients, Survivors, and Loved Ones July 2018 Lymphoma Research Foundation (LRF) Helpline and Clinical Trials Information Service CONTACT THE LRF HELPLINE Trained staff are available to answer questions and provide support to patients, caregivers and healthcare professionals in any language. Our support services include: • Information on lymphoma, treatment options, side effect management and current research fi ndings • Financial assistance for eligible patients and referrals for additional fi nancial, legal and insurance help • Clinical trial searches based on patient’s diagnosis and treatment history • Support through LRF’s Lymphoma Support Network, a national one-to one volunteer patient peer program Monday through Friday, Toll-Free (800) 500-9976 or email [email protected] Understanding Non-Hodgkin Lymphoma A Guide For Patients, Survivors, and Loved Ones July 2018 This guide is an educational resource compiled by the Lymphoma Research Foundation to provide general information on adult non- Hodgkin lymphoma. Publication of this information is not intended to replace individualized medical care or the advice of a patient’s doctor. Patients are strongly encouraged to talk to their doctors for complete information on how their disease should be diagnosed, treated, and followed. Before starting treatment, patients should discuss the potential benefits and side effects of cancer therapies with their physician. Contact the Lymphoma Research Foundation Helpline: (800) 500-9976 [email protected] Website: lymphoma.org This patient guide is supported through unrestricted educational grants from: © 2018 Lymphoma Research Foundation. Information contained herein is the property of the Lymphoma Research Foundation (LRF). Any portion may be reprinted or reproduced provided that LRF is acknowledged to be the source and the Foundation’s website (lymphoma.org) is included in the citation.
    [Show full text]
  • 1 Title: Biodistribution and Dosimetry Results from a Phase 1 Trial of 177Lu
    Downloaded from jnm.snmjournals.org by Oslo universitetssykehus, on January 31, 2019. For personal use only. Journal of Nuclear Medicine, published on August 28, 2017 as doi:10.2967/jnumed.117.195347 Title: Biodistribution and dosimetry results from a phase 1 trial of 177Lu-lilotomab satetraxetan antibody-radionuclide-conjugate therapy Johan Blakkisrud1, Jon Erik Holtedahl1 Ayca Løndalen2 , Jostein Dahle3 Tore Bach-Gansmo2, Harald Holte4, Stine Nygaard4 , Arne Kolstad4, Caroline Stokke1,5 1Department of Diagnostic Physics, Oslo University Hospital, Oslo, NORWAY 2Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY 3Nordic Nanovector ASA, Oslo, NORWAY 4Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, NORWAY 5Oslo and Akershus University College of Applied Science, Oslo, NORWAY Disclaimer: The LYMRIT37-01 study is sponsored by Nordic Nanovector ASA. Johan Blakkisrud is supported by grants from the South-Eastern Norway Regional Health Authority. Harald Holte and Arne Kolstad were both in part supported by grants from the Norwegian Cancer Society. Arne Kolstad is member of Scientific Advisory Board of Nordic Nanovector. Jostein Dahle is an employee and shareholder of Nordic Nanovector ASA. Corresponding author: Johan Blakkisrud, Department of Diagnostic Physics, Oslo University Hospital, Gaustad sykehus bygg 20, P.box 4959 Nydalen, 0424 Oslo, NORWAY, Telephone: (0047)481 46 588, Email: [email protected] First author: Johan Blakkisrud Word count: 4993 Running title: 177Lu-lilotomab satetraxetan dosimetry 1 Downloaded from jnm.snmjournals.org by Oslo universitetssykehus, on January 31, 2019. For personal use only. ABSTRACT 177Lu-lilotomab satetraxetan is a novel antibody radionuclide conjugate (ARC) currently in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indolent non- Hodgkin lymphoma (NHL).
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
    US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]